Amgen names James Bradner as EVP R&D/CSO; David Reese transitions to CTO

AMGEN INC

James Bradner, formerly President of Novartis Institutes for BioMedical Research, joins as EVP R&D and CSO effective Dec 18, 2023.
David M. Reese moves from EVP R&D to newly created EVP and Chief Technology Officer role effective Dec 18, 2023.
Both executives report to Chairman and CEO Robert A. Bradway.
Reese will lead acceleration of AI and technology across Amgen; he was key architect of Amgen's AI initiatives.
Announcement made Dec 14, 2023; appointments underscore Amgen's push to converge biotech and tech.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James Bradner

Executive Vice President, Research and Development, and Chief Scientific Officer

AMGN · AMGEN INC

Effective: 2023-12-18
Filed: December 14, 2023, 6:59 PM ET

James Bradner, M.D., has been hired as the Company’s Executive Vice President, Research and Development, and Chief Scientific Officer, an executive officer position.

Role change

David M. Reese

Executive Vice President and Chief Technology Officer

AMGN · AMGEN INC

Effective: 2023-12-18
Filed: December 14, 2023, 6:59 PM ET

David M. Reese, M.D., will transition from Executive Vice President, Research and Development to Executive Vice President and Chief Technology Officer, a newly created executive officer position, responsible for accelerating the use of technology and artificial intelligence (AI) across all facets of Amgen Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

James Bradner was appointed as Executive Vice President, Research and Development, and Chief Scientific Officer at AMGEN INC.

Action: hired
Role: Executive Vice President, Research and Development, and Chief Scientific Officer

Exact text from the filing

James Bradner, M.D., has been hired as the Company’s Executive Vice President, Research and Development, and Chief Scientific Officer, an executive officer position.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

David M. Reese changed role as Executive Vice President and Chief Technology Officer at AMGEN INC.

Action: transition
Role: Executive Vice President and Chief Technology Officer

Exact text from the filing

David M. Reese, M.D., will transition from Executive Vice President, Research and Development to Executive Vice President and Chief Technology Officer, a newly created executive officer position, responsible for accelerating the use of technology and artificial intelligence (AI) across all facets of Amgen Inc.

View on SEC.gov

AMGEN INC filing history →

Source: SEC EDGAR

accession 0001193125-23-295027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.